Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Nov

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Welcome and Introduction to Vi3C

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

FDA Approves Ziftomenib for NPM1-Positive AML

Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

Ezabenlimab, Induction Chemotherapy, and Adaptive Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma

Transfusion Access Prioritized Over Routine Hospice Services Among Patients With Blood Cancers